Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19

Hemodialysis patients (HD) are expected to have excess mortality in coronavirus disease 2019 (COVID-19). This was challenged by a recent study reporting HD patients to have comparable mortality and less ICU admissions when hospitalized with COVID-19. An altered immune system due to chronic inflammation might protect HD-patients from severe COVID-19. Therefore, we aimed to describe the peripheral blood immune phenotype in HD-patients and respective controls with COVID-19. Methods Sixty-four patients (31 HD, 33 non-HD) with PCR-confirmed COVID-19 and 16 control patients (10 HD, 6 non-HD) were prospectively included. According to symptoms, COVID-19 patients were categorized as asymptomatic/mild, moderate or severe COVID-19 phenotypes. Cytokine profiling and immune phenotyping was performed. Results Th1 and Th17 plasma cytokine levels were highly increased in HD patients without COVID-19 and were not significantly regulated during COVID-19. In non-HD COVID-19 patients these cytokines increased significantly with disease severity. While all patients with moderate or severe COVID-19 showed hallmarks of COVID-19 such as decreased CD3+, CD4+ and CD8+ and CD4+CD25hiFoxP3+ regulatory T cells, significantly increased CD38+CD8+ effector memory and CD38+CD8+ TEMRA T cells were detected in moderate/severe COVID-19 HD patients, which was not observed in non-HD patients with moderate or severe COVID-19. Furthermore, CD161+CD8+ T cells decreased significantly in non-HD COVID-19 patients dependent on disease severity, but not in HD patients. Dynamics of B cells and subtypes were comparable in HD and non-HD COVID-19 patients. Conclusions HD patients might be protected from severe COVID-19 due to their chronic inflammatory state with increased CD38+CD8+ effector memory and TEMRA T cells as well as CD161+CD8+ T cells.

[1]  C. Putensen,et al.  Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help , 2021, Cell Reports.

[2]  Md. Sahidul Islam,et al.  The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment , 2021, International journal of biological sciences.

[3]  B. Haditsch,et al.  T Cell Phenotyping in Individuals Hospitalized with COVID-19 , 2021, The Journal of Immunology.

[4]  J. Levitt,et al.  CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential , 2021, Frontiers in Immunology.

[5]  A. Sette,et al.  Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.

[6]  Konrad U. Förstner,et al.  Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19 , 2020, Immunity.

[7]  R. Valenta,et al.  Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations , 2020, Allergy.

[8]  Benjamin S. Glicksberg,et al.  Outcomes of Patients on Maintenance Dialysis Hospitalized with COVID-19. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[9]  A. Sette,et al.  Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19 , 2020, Cell.

[10]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[11]  C. Wanner,et al.  Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe , 2020, Kidney International.

[12]  Xiaowen Jiang,et al.  Characteristics of immune cells and cytokines in patients with coronavirus disease 2019 in Guangzhou, China , 2020, Human Immunology.

[13]  R. Cox,et al.  Not just antibodies: B cells and T cells mediate immunity to COVID-19 , 2020, Nature Reviews Immunology.

[14]  N. Koulouris,et al.  Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison , 2020, Nature Immunology.

[15]  M. Abate,et al.  Outcomes of patients with end-stage kidney disease hospitalized with COVID-19 , 2020, Kidney International.

[16]  Aaron M. Rosenfeld,et al.  Comprehensive mapping of immune perturbations associated with severe COVID-19 , 2020, Science Immunology.

[17]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[18]  K. Bhaskaran,et al.  Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.

[19]  D. Gladstone,et al.  Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports , 2020, Annals of Internal Medicine.

[20]  S. Mehrotra,et al.  CD38: T Cell Immuno-Metabolic Modulator , 2020, Cells.

[21]  Fang Lin,et al.  Clinical and pathological investigation of patients with severe COVID-19 , 2020, JCI Insight.

[22]  A. Gharavi,et al.  Presentation and Outcomes of Patients with ESKD and COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[23]  M. Ono,et al.  T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis , 2020, bioRxiv.

[24]  I. Amit,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[25]  Hui Tang,et al.  Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China. , 2020, Journal of the American Society of Nephrology : JASN.

[26]  R. Jin,et al.  High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[27]  M. Girardis,et al.  Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia , 2020, Nature Communications.

[28]  B. Cowie,et al.  Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 , 2020, Nature Medicine.

[29]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Scott A. Jenks,et al.  Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations , 2019, Front. Immunol..

[31]  V. Badovinac,et al.  Defining Memory CD8 T Cell , 2018, Front. Immunol..

[32]  D. Pleguezuelo,et al.  CD19+ B-Cells, a New Biomarker of Mortality in Hemodialysis Patients , 2018, Front. Immunol..

[33]  C. Ahn,et al.  Two case reports , 2017, Medicine.

[34]  M. Rugeles,et al.  Role of Different Subpopulations of CD8+ T Cells during HIV Exposure and Infection , 2017, Front. Immunol..

[35]  N. Shah,et al.  Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. , 2014, The Journal of clinical investigation.

[36]  M. Betjes.  Immune cell dysfunction and inflammation in end-stage renal disease , 2013, Nature Reviews Nephrology.

[37]  B. Chung,et al.  B cell-associated immune profiles in patients with end-stage renal disease (ESRD) , 2012, Experimental & Molecular Medicine.

[38]  B. Lask,et al.  Implications for Treatment , 2011 .

[39]  M. Betjes,et al.  Premature aging of circulating T cells in patients with end-stage renal disease. , 2011, Kidney international.

[40]  J. Carrero,et al.  Monitoring of inflammation in patients on dialysis: forewarned is forearmed , 2011, Nature Reviews Nephrology.

[41]  S. Zeuzem.  Forewarned is forearmed. , 2009, Journal of hepatology.

[42]  Wei Wang,et al.  Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals , 2008, The Journal of experimental medicine.

[43]  Andrew J. McMichael,et al.  Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets1 , 2005, The Journal of Immunology.

[44]  B. Psaty,et al.  Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. , 2005, JAMA.

[45]  F. Dekker,et al.  Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. , 2004, Journal of the American Society of Nephrology : JASN.

[46]  B. Memoli.  Cytokine Production in Haemodialysis , 1999, Blood Purification.

[47]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[48]  P. Kimmel,et al.  Immunologic function and survival in hemodialysis patients. , 1998, Kidney international.

[49]  T. Luger,et al.  Blood-membrane interaction in hemodialysis leads to increased cytokine production. , 1987, Kidney international.